MX9305056A - Composicion reguladora de apoptosis. - Google Patents
Composicion reguladora de apoptosis.Info
- Publication number
- MX9305056A MX9305056A MX9305056A MX9305056A MX9305056A MX 9305056 A MX9305056 A MX 9305056A MX 9305056 A MX9305056 A MX 9305056A MX 9305056 A MX9305056 A MX 9305056A MX 9305056 A MX9305056 A MX 9305056A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic agents
- apoptosis
- agents
- salts
- regulatory composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proveen composiciones reguladoras de apoptosis, cada una comprendiendo un miembro seleccionado de una serie de derivados de carboestirilo y sales de los mismos, incluyendo derivados de carboestirilo de la fórmula general (I) (Ver Fórmula); y sales de los mismos, como un ingrediente activo. Las composiciones reguladoras de apoptosis de la invención son útiles como agentes anticáncer, agentes antirretrovirus, agentes terapéuticos para enfermedades autoinmunes, agentes terapéuticos para trombocitopenia, agentes terapéuticos para la enfermedad de Alzheimer, agentes terapéuticos para enfermedades del hígado, de inhibidores de metástasis de cáncer, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22037392 | 1992-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9305056A true MX9305056A (es) | 1994-04-29 |
Family
ID=16750110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9305056A MX9305056A (es) | 1992-08-19 | 1993-08-19 | Composicion reguladora de apoptosis. |
Country Status (8)
Country | Link |
---|---|
US (2) | US5464833A (es) |
EP (1) | EP0623598A4 (es) |
AU (1) | AU666577B2 (es) |
CA (1) | CA2121148A1 (es) |
MX (1) | MX9305056A (es) |
PH (1) | PH30152A (es) |
TW (1) | TW240168B (es) |
WO (1) | WO1994004504A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521185A (en) * | 1993-03-02 | 1996-05-28 | Otsuka Pharmaceutical Co., Ltd. | Methods for inhibiting graft rejection and IL-1 production |
US5497913A (en) * | 1993-12-15 | 1996-03-12 | Denny D. Baker | Mixing bag arrangement and method |
EP0711356A4 (en) * | 1994-05-26 | 1999-11-24 | New York Medical College | DETECTION OF HALOGEN PRECURSORS INCORPORATED IN DNA |
US5504093A (en) * | 1994-08-01 | 1996-04-02 | Otsuka Pharmaceutical Co., Ltd. | Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication |
CA2158822C (en) * | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
US5620888A (en) * | 1994-12-29 | 1997-04-15 | Lxr Biotechnology, Inc. | Cell strains for use in identifying potentially therapeutically effective agents |
US5571523A (en) * | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
WO1998046229A1 (fr) * | 1995-06-21 | 1998-10-22 | Otsuka Pharmaceutical Co., Ltd. | Inhibiteurs de la production d'il-8 et du mcaf |
WO1997008345A1 (en) * | 1995-08-30 | 1997-03-06 | New York Medical College | Methods for labeling dna ends with halogenated nucleotides and detecting same with antibodies |
US5846758A (en) * | 1995-11-30 | 1998-12-08 | His Excellency Ghassan I. Shaker | Method for diagnosing autoimmune diseases |
JP2000505471A (ja) * | 1996-02-28 | 2000-05-09 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲン受容体拮抗物質 |
US5780480A (en) * | 1996-02-28 | 1998-07-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US20020151063A1 (en) * | 1996-08-30 | 2002-10-17 | Annette Lasham | Methods for modulating apoptotic cell death |
US5912168A (en) * | 1996-08-30 | 1999-06-15 | Genesis Research & Development Corporation Limited | CD95 regulatory gene sequences |
US6180402B1 (en) | 1996-11-20 | 2001-01-30 | Qlt Inc. | Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor |
AU6854398A (en) * | 1997-04-25 | 1998-11-24 | Otsuka Pharmaceutical Co., Ltd. | Hyaluronate synthesis inhibitors |
TWI244484B (en) * | 1998-06-09 | 2005-12-01 | Takara Bio Inc | Pharmaceutical composition containing oxy-containing hexacyclic compound |
ES2533255T3 (es) | 1998-07-13 | 2015-04-08 | Board Of Regents, The University Of Texas System | Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer |
SI1107795T1 (en) | 1998-09-04 | 2003-06-30 | The Regents Of The University Of Michigan | Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis |
AU5877500A (en) * | 1999-06-15 | 2001-01-02 | Neurogen Corporation | Piperidinyl and piperazinyl substituted benzofused lactams |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
WO2002098425A1 (en) * | 2001-06-04 | 2002-12-12 | Cytovia, Inc. | Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
GB0124848D0 (en) * | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
US7354928B2 (en) * | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
CN104225610B (zh) | 2002-07-15 | 2017-03-01 | 得克萨斯大学体系董事会 | 与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗用途 |
US8431396B2 (en) | 2003-03-21 | 2013-04-30 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
CA2553690C (en) | 2004-01-22 | 2016-05-24 | Sung Lan Hsia | Topical co-enzyme q10 formulations and methods of use |
MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
GB2532990A (en) | 2014-12-05 | 2016-06-08 | Schlumberger Holdings | Corrosion inhibition |
GB2543498A (en) * | 2015-10-19 | 2017-04-26 | Schlumberger Holdings | Corrosion inhibition |
CN107174584B (zh) * | 2016-03-12 | 2020-09-01 | 福建金乐医药科技有限公司 | 含哌嗪结构化合物在制备lsd1抑制剂中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2931741A1 (de) * | 1979-08-04 | 1981-02-26 | Thomae Gmbh Dr K | Arzneimittel zur vermeidung von tumormetastierung |
JPS6038384B2 (ja) * | 1978-03-24 | 1985-08-31 | 大塚製薬株式会社 | チオセミカルバゾン誘導体 |
JPS5742673A (en) * | 1980-08-29 | 1982-03-10 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
JPS5777676A (en) * | 1980-10-31 | 1982-05-15 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
JPS5883677A (ja) * | 1981-11-11 | 1983-05-19 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
JPS5929667A (ja) * | 1982-08-13 | 1984-02-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体および強心剤 |
JPS59104378A (ja) * | 1982-12-03 | 1984-06-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
US4677112A (en) * | 1984-02-02 | 1987-06-30 | Warner-Lambert Company | 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators |
US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
JPH07100696B2 (ja) * | 1984-12-18 | 1995-11-01 | 大塚製薬株式会社 | カルボスチリル誘導体 |
US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
DE3526044A1 (de) * | 1985-07-20 | 1987-01-22 | Hoechst Ag | Dihydrochinolinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung, sowie zwischenprodukte zu ihrer herstellung |
JPS62135423A (ja) * | 1985-12-09 | 1987-06-18 | Otsuka Pharmaceut Co Ltd | 低酸素症改善剤 |
DK588486A (da) * | 1985-12-09 | 1987-06-10 | Otsuka Pharma Co Ltd | Anvendelse af en forbindelse til behandling af hypoxi |
JPS63225357A (ja) * | 1987-03-12 | 1988-09-20 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
US5185346A (en) * | 1988-11-29 | 1993-02-09 | Hanssen Pharmaceutica | (1H-azol-1-ylmethyl)substituted quinoline derivatives |
TW201305B (es) * | 1991-04-03 | 1993-03-01 | Otsuka Pharma Co Ltd | |
DE69230131T2 (de) * | 1991-07-03 | 2000-03-02 | Otsuka Pharmaceutical Co., Ltd. | Apoptoseregulator |
JPH05320133A (ja) * | 1991-07-18 | 1993-12-03 | Japan Tobacco Inc | 3,4−ジヒドロ−2(1h)−キノリノン誘導体 |
JP2597953B2 (ja) * | 1991-12-10 | 1997-04-09 | 大塚製薬株式会社 | 制癌剤 |
JPH0612248A (ja) * | 1992-04-02 | 1994-01-21 | Hitachi Ltd | プログラムの自動生成方式 |
-
1993
- 1993-08-12 CA CA002121148A patent/CA2121148A1/en not_active Abandoned
- 1993-08-12 WO PCT/JP1993/001144 patent/WO1994004504A1/ja not_active Application Discontinuation
- 1993-08-12 EP EP94908099A patent/EP0623598A4/en not_active Withdrawn
- 1993-08-12 US US08/211,818 patent/US5464833A/en not_active Expired - Fee Related
- 1993-08-12 AU AU47615/93A patent/AU666577B2/en not_active Ceased
- 1993-08-18 TW TW082106642A patent/TW240168B/zh active
- 1993-08-18 PH PH46711A patent/PH30152A/en unknown
- 1993-08-19 MX MX9305056A patent/MX9305056A/es unknown
-
1995
- 1995-08-29 US US08/520,478 patent/US5691341A/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU4761593A (en) | 1994-03-15 |
EP0623598A1 (en) | 1994-11-09 |
EP0623598A4 (en) | 1997-05-02 |
AU666577B2 (en) | 1996-02-15 |
US5464833A (en) | 1995-11-07 |
WO1994004504A1 (en) | 1994-03-03 |
US5691341A (en) | 1997-11-25 |
PH30152A (en) | 1997-01-21 |
CA2121148A1 (en) | 1994-03-03 |
TW240168B (es) | 1995-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9305056A (es) | Composicion reguladora de apoptosis. | |
CO4930259A1 (es) | Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen | |
UY26968A1 (es) | Agentes terapéuticos | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
ES2161290T3 (es) | Derivados de quinazolina. | |
ES2196377T3 (es) | Derivados de naftiridina. | |
PA8480101A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
AR029766A1 (es) | Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica | |
ES2112650T3 (es) | Sales de un derivado de indol antimigraña. | |
ES2185999T3 (es) | Derivados de quinazolina y composiciones farmaceuticas que los contienen. | |
AR023574A1 (es) | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios | |
MX9304138A (es) | Derivados de indol e indeno, procedimiento para supreparacion y composiciones farmaceuticas que los contienen. | |
PA8442001A1 (es) | Derivados de pirimidina biciclica condensada | |
ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
PA8507601A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
ES2191048T3 (es) | Derivados de oxazolidinona y compuestos farmaceuticos que los contienen. | |
BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
AR008164A1 (es) | Cetolidas 6-0-sustituidas que tienen actividad antibacteriana, procedimientos para su preparacion, uso de los mismos en la preparacion decomposiciones farmaceuticas y composiciones farmaceuticas | |
AR030933A1 (es) | Derivados del triazol y composiciones farmaceuticas que los contienen | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
ES2145774T3 (es) | Derivados de adenosina que tienen actividad agonista en a2. | |
GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
PA8518701A1 (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
AR028948A1 (es) | Compuestos novedosos |